Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2025)
Jazz Pharmaceuticals' (JAZZ) quarterly Income from Non-Controlling Interests came in at -$147000.0 in Q1 2025, down 108.55% year-on-year from $1.7 million in Q1 2024, and down 108.55% quarter-over-quarter from $1.7 million in Q1 2024.
Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2025) Analysis & Trends
Jazz Pharmaceuticals' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$147000.0 for Q1 2025.
- On a quarterly basis, Income from Non-Controlling Interests fell 108.55% year-over-year to -$147000.0 in Q1 2025; TTM through Mar 2025 was $1.6 million, a 8.55% decrease from a year earlier, with the FY2015 full-year figure at -$1000.0, up 99.91% from the prior year.
- Income from Non-Controlling Interests fell to -$147000.0 in Q1 2025 per JAZZ's latest filing, from $1.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.7 million in Q1 2024 and bottomed at -$147000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.77 Bn | 13.93 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -147,000.00 |
| Mar 31, 2024 | 1.72 Mn |
| Jun 30, 2015 | -1,000.00 |
| Dec 31, 2014 | -1,000.00 |
| Sep 30, 2014 | 2,000.00 |
| Jun 30, 2014 | -73,000.00 |
| Mar 31, 2014 | -989,000.00 |